SCHEMBL332813

SCHEMBL332813

CN(C)CCN(CCO)CCO

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.65
CA12 O43570 1/20 0.42
CA2 P00918 1/20 0.42
CA3 P07451 1/20 0.42
CA4 P22748 1/20 0.42
CA6 P23280 1/20 0.42
CA5A P35218 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42
CA5B Q9Y2D0 1/20 0.42
KDM4E B2RXH2 1/20 0.37
ALOX15 P16050 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ALDH1A1 P00352 2/20 0.35
TSHR P16473 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13187870 1.00 MAPT (0.65) MAPTCA12CA2CA3CA4
SCHEMBL5891988 1.00 MAPT (0.65) MAPTCA12CA2CA3CA4
Hydrochloric Acid SCHEMBL27157431 0.97 MAPT (0.61) MAPTCA12CA2CA3CA4
Trolamine SCHEMBL28044314 0.97 MAPT (0.69) MAPTCA12CA2CA3CA4
Trolamine SCHEMBL15410677 0.90 MAPT (0.80) MAPTCA12CA2CA3CA4
SCHEMBL23117067 0.89 MAPT (0.52) MAPTCA12CA2CA3CA4
SCHEMBL9715505 0.89 MAPT (0.52) MAPTCA12CA2CA3CA4
SCHEMBL28594961 0.87 MAPT (0.50) MAPTCA12CA2CA3CA4
SCHEMBL23117107 0.86 MAPT (0.55) MAPTCA12CA2CA3CA4
SCHEMBL2845499 0.86 MAPT (0.55) MAPTCA12CA2CA3CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2878609-B1 AMINE CATALYST FOR CURING POLYISOCYANATE COMPOUND AND POLYISOCYANATE ADHESIVE COMPOSITION CONTAINING AMINE CATALYST FOR CURING POLYISOCYANATE COMPOUND TOSOH CORP (JP) 2019-06-05 EP claimed
US-9777199-B2 Amine catalyst for curing polyisocyanate compound and polyisocyanate adhesive composition containing amine catalyst for curing polyisocyanate compound TOSOH CORPORATION (JP) 2017-10-03 US claimed
US-20150203727-A1 AMINE CATALYST FOR CURING POLYISOCYANATE COMPOUND AND POLYISOCYANATE ADHESIVE COMPOSITION CONTAINING AMINE CATALYST FOR CURING POLYISOCYANATE COMPOUND TOSOH CORPORATION (JP) 2015-07-23 US claimed
EP-2878609-A1 AMINE CATALYST FOR CURING POLYISOCYANATE COMPOUND AND POLYISOCYANATE ADHESIVE COMPOSITION CONTAINING AMINE CATALYST FOR CURING POLYISOCYANATE COMPOUND Tosoh Corporation (JP) 2015-06-03 EP claimed
US-8222311-B2 Hydroxyalkylated polyalkylenepolyamine composition, method of producing the same and their use in polyurethanes TOSOH CORPORATION (JP) 2012-07-17 US claimed
US-20080004362-A1 Hydroxyalkylated Polyalkylenepolyamine Composition, Method for Producing Same and Method for Producing Polyurethane Resin Using Such Hydroxyalkylated Polyalkylenepolyamine Composition TOSOCH CORPORATION (JP) 2008-01-03 US claimed
EP-1813599-A1 HYDROXYALKYLATED POLYALKYLENEPOLYAMINE COMPOSITION, METHOD FOR PRODUCING SAME AND METHOD FOR PRODUCING POLYURETHANE RESIN USING SUCH HYDROXYALKYLATED POLYALKYLENEPOLYAMINE COMPOSITION Tosoh Corporation (JP) 2007-08-01 EP claimed
EP-1092737-B1 Catalyst composition for the production of a polyurethane resin, and method for producing a polyurethane resin TOSOH CORP (JP) 2003-09-24 EP claimed
US-6596663-B1 Reacting a polyol with an organic polyisocyanate in the presence of a diamine catalyst and, if necessary, a blowing agent, a surfactant, a cross-linking agent TOSOH CORPORATION (JP) 2003-07-22 US claimed
US-6342169-B1 ABSORPTION OF SALT FORM IN WATER MEDIUM CONTAINING WATER SOLUBLE AMINE; SATURATION; STORAGE STABILITY CANSOLV TECHNOLOGIES, INC. (CA) 2002-01-29 US claimed
EP-1092737-A2 Catalyst composition for the production of a polyurethane resin, and method for producing a polyurethane resin Tosoh Corporation (JP) 2001-04-18 EP claimed
EP-0552360-A1 A COMPOSITION AND METHOD FOR SIMULTANEOUS ABSORPTION OF SULFUR DIOXIDE AND NITRIC OXIDE THE DOW CHEMICAL COMPANY (US) 1993-07-28 EP claimed
WO-1993003825-A1 A COMPOSITION AND METHOD FOR SIMULTANEOUS ABSORPTION OF SULFUR DIOXIDE AND NITRIC OXIDE THE DOW CHEMICAL COMPANY (US) 1993-03-04 WO claimed
EP-4332086-B1 COMPOUND OR SALT THEREOF, LIPID PARTICLES, AND PHARMACEUTICAL COMPOSITION FUJIFILM CORP (JP) 2026-04-08 EP disclosed
US-20240255403-A1 POLYURETHANE-CONTAINING NON-FOAMED MOLDED BODY CANON KABUSHIKI KAISHA (JP) 2024-08-01 US disclosed
EP-4397466-A1 POLYURETHANE-CONTAINING NON-FOAMED MOLDED BODY CANON KABUSHIKI KAISHA (JP) 2024-07-10 EP disclosed
WO-1993003825-A1 A COMPOSITION AND METHOD FOR SIMULTANEOUS ABSORPTION OF SULFUR DIOXIDE AND NITRIC OXIDE THE DOW CHEMICAL COMPANY (US) 1993-03-04 WO disclosed
US-5128408-A Quaternized amino polyurethane- or polyurethaneurea-polysiloxanes treated with heparin TOYO BOSEKI KABUSHIKI KAISHA (JP) 1992-07-07 US disclosed
US-5019361-A Removal and recovery of sulphur dioxide from gas streams UNION CARBIDE CANADA LIMITED (US) 1991-05-28 US disclosed
US-4158672-A OIL AND WATER REPELLENTS FOR TEXTILES CIBA-GEIGY CORPORATION (US) 1979-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004362-A1 Hydroxyalkylated Polyalkylenepolyamine Composition, Method for Producing Same and Method for Producing Polyurethane Resin Using Such Hydroxyalkylated Polyalkylenepolyamine Composition SRM, HRH3, HNMT MAPT 3900/4885CA12 4484/4885CA2 3948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.